<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" public-private="public"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 S1239 IS: Scleroderma Research and Awareness Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2013-06-27</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code> 
<congress>113th CONGRESS</congress> <session>1st Session</session> 
<legis-num>S. 1239</legis-num> 
<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber> 
<action> 
<action-date date="20130627">June 27, 2013</action-date> 
<action-desc><sponsor name-id="S331">Mrs. Gillibrand</sponsor> introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc> 
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To expand the research and awareness activities of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the Centers for Disease Control and Prevention with respect to scleroderma, and for other purposes.</official-title> 
</form> 
<legis-body style="OLC"> 
<section id="H94108626BE1E4AEBB01C98AD4D308BF" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Scleroderma Research and Awareness Act</short-title></quote>.</text> </section>
<section id="HE5095A7CDD3D494C9E00FBF24EEAE6E8"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">The Congress finds as follows:</text> 
<paragraph id="H718B48B08D944621A8B935C4E3173188"><enum>(1)</enum><text>Scleroderma is a chronic, disabling and often fatal autoimmune disease in which the body’s soft tissues contract and harden due to an overproduction of collagen.</text> </paragraph>
<paragraph id="HEB66FE7C5C4F480ABA36647D23337500"><enum>(2)</enum><text>Scleroderma causes damage to one or more of the body’s organ systems, including the skin, heart, lungs, kidneys, gastrointestinal tract, and blood vessels.</text> </paragraph>
<paragraph id="HAA7838BE35CA4FE2BF901FC95CE9001E"><enum>(3)</enum><text>It is estimated that 300,000 people in the United States suffer from scleroderma, 80 percent of whom are women often diagnosed during their child bearing years.</text> </paragraph>
<paragraph id="HBCD6087CF9CF4607A23E73AF60D6B98"><enum>(4)</enum><text>Choctaw Native Americans, African-Americans, and Hispanics are disproportionately affected by scleroderma and tend to exhibit more rapidly progressing and severe cases of the disease.</text> </paragraph>
<paragraph id="H9C28CFF2375D4B829500C6C740AFA8D8"><enum>(5)</enum><text>The causes of scleroderma are unknown.</text> </paragraph>
<paragraph id="HB33F0CC9376042BD9EC033BE23003B11"><enum>(6)</enum><text>Scleroderma is associated with many other conditions including pulmonary hypertension, gastroparesis, Raynaud’s phenomenon, Sjögren’s Syndrome and lupus.</text> </paragraph>
<paragraph id="H7451017D2DA84B9183DBDFA3AAC74158"><enum>(7)</enum><text>The estimated total annual economic impact of scleroderma in the United States is in excess of $1,500,000,000.</text> </paragraph>
<paragraph id="H2BBF7CB357F04541B785E7BA594C2B27"><enum>(8)</enum><text>Annual Federal support for scleroderma research at the National Institutes of Health is currently estimated at $20,000,000.</text> </paragraph></section>
<section id="HCD9864E411244E6FB3CC141D57004983"><enum>3.</enum><header>National institute of arthritis and musculoskeletal and skin diseases; scleroderma research expansion</header> 
<subsection id="H21DC7D2591F0483C9B9D573931D22FAE"><enum>(a)</enum><header>In general</header><text>The Director of The National Institute of Arthritis and Musculoskeletal and Skin Diseases shall expand, intensify, and coordinate the activities of the Institute with respect to scleroderma, with particular emphasis on the following areas:</text> 
<paragraph id="H8B443044906D47C7B8B859E1B992B84"><enum>(1)</enum><text>Research focused on the etiology of scleroderma and the development of new treatment options.</text> </paragraph>
<paragraph id="H30722E46D8BF414A92E5DB3FAEF90DE"><enum>(2)</enum><text>Clinical research to evaluate new treatments options.</text> </paragraph>
<paragraph id="HC6098E0F8F834364B98EFE15AF777B0"><enum>(3)</enum><text>Basic research on the relationship between scleroderma and secondary conditions such as pulmonary hypertension, gastroparesis, Raynaud’s phenomenon, Sjögren’s Syndrome (and other diseases as determined by the Director).</text> </paragraph>
<paragraph id="H53BAAC63B128448EB77087C7AEBB4DE0"><enum>(4)</enum><text>Establishment of scleroderma patient registries, including family and childhood onset registries.</text> </paragraph>
<paragraph id="H9A56901C788942C68B11EEC62F00E29C"><enum>(5)</enum><text>Support for training of new clinicians and investigators with expertise in scleroderma.</text> </paragraph></subsection>
<subsection id="H38B66E51AEFF4F80A1FD67698C7900AF"><enum>(b)</enum><header>Biennial reports</header><text>As a part of the biennial report made under section 403 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/283">42 U.S.C. 283</external-xref>), the Secretary shall include information on the status of scleroderma research at the National Institutes of Health.</text> </subsection>
<subsection id="HB3B9F0F2C9D34036A5B0DD7DDC4F400"><enum>(c)</enum><header>Authorization of appropriations</header> 
<paragraph id="H9C85DF7923B34149B2124479D993001"><enum>(1)</enum><header>In general</header><text>For the purpose of carrying out subsection (a), there are authorized to be appropriated $25,000,000 in fiscal year 2014, $30,000,000 in fiscal year 2015, and $35,000,000 in fiscal year 2016.</text> </paragraph>
<paragraph id="H4258883D02784BACB989FA00E3D1A0BB"><enum>(2)</enum><header>Reservations</header><text>Of the amounts authorized to be appropriated under paragraph (1), not more than 15 percent shall be reserved for the training of qualified health professionals in biomedical research focused on scleroderma.</text> </paragraph></subsection></section>
<section id="H0ED8B5154E8B438E81DD087FDD44E474"><enum>4.</enum><header>Promoting public awareness of scleroderma</header> 
<subsection id="H6BFBF563B90A489087C2D19C389E334E"><enum>(a)</enum><header>In General</header><text>The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall carry out an educational campaign to increase public awareness of scleroderma. Print, video, and Web-based materials distributed under this program may include—</text> 
<paragraph id="H86D02FA87E1948F8A979C0943E372547"><enum>(1)</enum><text>basic information on scleroderma and its symptoms;</text> </paragraph>
<paragraph id="H5DDC964845F544B1B04E7FD16C6988A7"><enum>(2)</enum><text>information on the incidence and prevalence of scleroderma;</text> </paragraph>
<paragraph id="H49EE3854893B4181B4ABC51EA6B551B6"><enum>(3)</enum><text>diseases and conditions affiliated with scleroderma; or</text> </paragraph>
<paragraph id="H2DCCA86E069F4697B7DCD27671D7D8BA"><enum>(4)</enum><text>the importance of early diagnosis and treatment.</text> </paragraph></subsection>
<subsection id="HCCCE0EAECFD14926A8BA7DB47F9F7067"><enum>(b)</enum><header>Dissemination of Information</header><text>The Secretary is encouraged to disseminate information under subsection (a) through a cooperative agreement with a national nonprofit entity with expertise in scleroderma.</text> </subsection>
<subsection id="HC2294FF45EFB49F6B861CB30B3E79DFB"><enum>(c)</enum><header>Report to Congress</header><text>Not later than September 30, 2013, the Secretary shall report to the Committees on Health, Education, Labor, and Pensions and Appropriations of the Senate and the Committees on Energy and Commerce and Appropriations of the House of Representatives on the status of activities under this section.</text> </subsection>
<subsection id="H68266477FA874C4B9251A600B24E06BD"><enum>(d)</enum><header>Authorization of Appropriations</header><text>For the purpose of carrying out this section, there is authorized to be appropriated $2,500,000 for each of fiscal years 2014, 2015, and 2016.</text> </subsection></section>
</legis-body> 
</bill> 


